SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)
In development [GID-MT526] Expected publication date: TBC
Search results
511 results
-
-
Endo-SPONGE for treating low rectal anastomotic leakage (MT461)
In development [GID-MT539] Expected publication date: TBC
-
Peezy Midstream for urine collection (MT446)
In development [GID-MT538] Expected publication date: TBC
-
The MAGEC system for spinal lengthening in children with scoliosis
In development [GID-MT544] Expected publication date: 15 September 2020
-
V.A.C. VERAFLO Therapy System for acute infected or chronic wounds that are failing to heal (MT471)
In development [GID-MT543] Expected publication date: 27 January 2020
-
Synergo for non-muscle-invasive bladder cancer
In development [GID-MT553] Expected publication date: TBC
-
Sleepio for adults with difficulty sleeping (MT443)
In development [GID-MT552] Expected publication date: 03 August 2021
-
Prontosan for acute and chronic wounds
In development [GID-MT551] Expected publication date: 05 October 2021
-
GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)
In development [GID-MT557] Expected publication date: 22 March 2022
-
DyeVert for reducing contrast media in coronary and peripheral angiography (MT488)
In development [GID-MT550] Expected publication date: 04 October 2021
-
DHT pilot: myCOPD for self-management of chronic obstructive pulmonary disease (COPD)
In development [GID-MT531] Expected publication date: TBC
-
Leukomed Sorbact for preventing surgical site infection (MT496)
In development [GID-MT541] Expected publication date: 03 February 2021
-
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MT241)
In development [GID-MT548] Expected publication date: 04 May 2021
-
MT507 Plus Sutures for preventing surgical site infection (MIB204)
In development [GID-MT558] Expected publication date: 09 November 2021
-
3C Patch System for treating diabetic foot ulcers (MT539)
In development [GID-MT559] Expected publication date: 19 January 2022
-
Danis Stent for acute oesophageal variceal bleeds (MT450)
In development [GID-MT537] Expected publication date: 25 May 2021
-
GID-MT554 KardiaMobile for the ambulatory detection of atrial fibrillation
In development [GID-MT554] Expected publication date: 06 January 2022
-
Alpha Stim AID (MT477)
In development [GID-MT542] Expected publication date: 08 March 2021
-
MT582 AnaConDa-S for sedation with volatile anaesthetics in intensive care
In development [GID-MT556] Expected publication date: 23 February 2022
-
Atezolizumab monotherapy for untreated PD-L1 positive metastatic non-small-cell lung cancer [ID1678]
In development [GID-TA10587] Expected publication date: 02 June 2021
-
Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]
In development [GID-TA10472] Expected publication date: 02 June 2021
-
Third molars (impacted) - prophylactic removal [ID898]
In development [GID-TAG525] Expected publication date: TBC
-
Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]
In development [GID-TA10705] Expected publication date: 15 September 2021
-
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]
In development [GID-TA10664] Expected publication date: TBC
-
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]
In development [GID-TA10611] Expected publication date: TBC
-
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629]
In development [GID-TA10576] Expected publication date: TBC
-
Enzalutamide with androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer ID1605
In development [GID-TA10488] Expected publication date: TBC
-
Omalizumab for treating chronic rhinosinusitis with nasal polyps [ID1650]
In development [GID-TA10558] Expected publication date: TBC
-
Pembrolizumab for previously treated endometrial cancer [ID1205]
In development [GID-TA10243] Expected publication date: TBC
-
Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289
In development [GID-TA10210] Expected publication date: TBC
-
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401
In development [GID-TA10326] Expected publication date: TBC
-
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
In development [GID-TA10405] Expected publication date: TBC
-
Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333]
In development [GID-TA10252] Expected publication date: TBC
-
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]
In development [GID-TA10223] Expected publication date: TBC
-
Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]
In development [GID-TA10465] Expected publication date: TBC
-
Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]
In development [GID-TA10486] Expected publication date: TBC
-
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]
In development [GID-TA10483] Expected publication date: TBC
-
Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma ID1466
In development [GID-TA10355] Expected publication date: TBC
-
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]
In development [GID-TA10248] Expected publication date: TBC
-
Talazoparib for treating BRCA 1 or 2 mutated advanced breast cancer after prior chemotherapy (ID1342)
In development [GID-TA10366] Expected publication date: TBC
-
Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer ID1404
In development [GID-TA10327] Expected publication date: 14 July 2021
-
Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143]
In development [GID-TA10186] Expected publication date: TBC
-
Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer ID1168
In development [GID-TA10208] Expected publication date: TBC
-
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]
In development [GID-TA10250] Expected publication date: TBC
-
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]
In development [GID-TA10607] Expected publication date: TBC
-
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]
In development [GID-TA10589] Expected publication date: TBC
-
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]
In development [GID-TA10573] Expected publication date: TBC
-
Nivolumab-relatlimab for untreated advanced or metastatic melanoma [ID1688]
In development [GID-TA10581] Expected publication date: TBC
-
Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]
In development [GID-TA10583] Expected publication date: TBC
-
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
In development [GID-TA10467] Expected publication date: TBC